Trump again tells people to take Hydroxychloroquine to treat COVID-19, despite a lack of evidence
April 6, 2020Sales and Marketing COVID-19, chloroquine, coronavirus, hydrochloroquine, hydroxychloroquine
President Trump continues to push the drug hydroxychloroquine as a potential coronavirus treatment despite a lack of evidence for its …
Pfizer scores EU approval for MabThera biosimilar Ruxience
April 6, 2020Sales and Marketing MabThera, Pfizer, Ruxience, biosimilar
The European Commission has moved to authorise Ruxience, Pfizer’s biosimilar version of MabThera (rituximab). The decision marks the seventh biosimilar …
Industry veteran Dr David Setboun joins BrainStorm as Executive VP and COO
April 3, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BrainStorm Therapeutics, appointments, pharma
BrainStorm Cell Therapeutics, a firm developing cellular therapies to tackle neurodegenerative diseases, has named industry Big Pharma veteran Dr David …
Dr John C. McKew promoted to Chief Operating Officer at Lumos Pharma
April 3, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Lumos Pharma, Inc. has promoted Dr John McKew to the position of Chief Operating Officer effective 1 April 2020. McKew …
Steven T Gill returns to Alimera as VP, Thought Leader Engagement
April 3, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alimera Sciences, Novartis, pharma
Ophthalmology specialist Alimera Sciences has announced that Steven T Gill is to return to the company in the newly created …
Top Ten most popular articles on Pharmafile.com this week
April 3, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, coronavirus
COVID-19 coronavirus treatments dominate the news as the world looks for a vaccine. Johnson & Johnson announced that it has …
MSD’s Keytruda hits Phase 3 main goal in first-line colorectal cancer sub-population
April 3, 2020Medical Communications, Research and Development MSD, colorectal cancer, keytruda, pharma
MSD has lifted the veil on new Phase 3 for its blockbuster immunotherapy Keytruda, showing that the anti-PD-1 therapy met …
British man charged in the US for smuggling phoney coronavirus cure
April 3, 2020Medical Communications COVID-19, COVID-19 vaccine, Coronavirus Cure, coronavirus
A British man has been accused of smuggling a fake coronavirus cure into the US and has been federally charged. …
Sanofi and Regeneron’s Dupixent combo impresses in paediatric atopic dermatitis
April 3, 2020Medical Communications, Research and Development Dupixent, Sanofi, atopic dermatitis, pharma
Sanofi and Regeneron have unveiled new Phase 3 data for their IL-4 and IL-13 inhibitor Dupixent (dupilumab), showing strong results …
EMA refuses to approve chloroquine for COVID-19 without sufficient data
April 3, 2020Medical Communications COVID-19, chloroquine, coronavirus
The European Medicines Agency has restricted the general use of the drug chloroquine for coronavirus, but allowing its testing in …
FDA calls for heartburn drug Zantac to be pulled due to carcinogen concerns
April 2, 2020Business Services FDA, NDMA, Sanofi, heartburn
The FDA is requesting that manufactures remove Zantac (ranitidine) from the market due to risks of it containing a carcinogen. …
US approval for haemophilia drug derived from genetically engineered rabbit’s milk
April 2, 2020Sales and Marketing FDA, US, haemophilia, pharma
The FDA has announced the approval of Sevenfact, a haemophilia therapy the active ingredient from which is expressed in genetically …
FDA places no penalties on Novartis after Zolgensma data manipulation investigation
April 2, 2020Business Services FDA, Novartis, regulators
The FDA has concluded its investigation into Novartis and its data manipulation of the gene therapy Zolgensma, and has decided …
EUSA Pharma’s COVID-19 drug improves or stabilises respiratory condition in 76% of patients
April 2, 2020Research and Development COVID-19, Eusa Pharma, coronavirus, ergomed, siltuximab
EUSA Pharma has unveiled promising preliminary findings from an interim analysis of siltuximab in the treatment of serious respiratory complications …
British American Tobacco creating coronavirus vaccine
April 2, 2020Business Services COVID-19, coronavirus
British American Tobacco has said it is developing a COVID-19 vaccine from tobacco plants. The owner of famous cigarette brands, …
Researchers modify T-cells to identify and target multiple sites on leukaemia cells
April 1, 2020Research and Development Cancer, Cancers, children cancer, leukaemia
Scientists from the Children’s Hospital of Los Angeles have engineered T-cells to identify and target multiple sites on acute lymphoblastic …
The April 2020 issue of Pharmafocus is available to read free online now!
April 1, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, UK, US, coronavirus, generic medicines, pharma, rare disease, real world data, real-world data
The latest monthly edition of Pharmafocus, the April 2020 issue, is available to read for free online now! There’s one …
FDA aims to accelerate COVID-19 therapies with new programme
April 1, 2020Research and Development COVID-19, FDA, america, coronaviurs
The FDA has launched the Coronavirus Treatment Acceleration Program (CTAP) to quickly bring therapies and treatments to people suffering from …
Europe sells Iran medicine, defying US sanctions
April 1, 2020Research and Development Iran, Iran Sanctions, Iran US, USA, coronavirus
France, Germany and the UK have announced the sale of medicinal goods to Iran, bypassing US sanctions on the country …
Lilly partners with Sitryx in $880m immunometabolism drug development deal
April 1, 2020Research and Development Eli Lilly, Sitryx, partnership, pharma
Eli Lilly and UK firm Sitryx have partnered up in a new drug development and commercialisation deal that could potentially …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
